ProCE Banner Activity

Interactive Decision Support Tool: Expert Management Recommendations for Patients With β-Thalassemia

Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with β-thalassemia with those of 4 renowned thalassemia experts.



Released: April 22, 2021

Expiration: April 21, 2022

No longer available for credit.

Share

Faculty

Jeanne Boudreaux

Jeanne Boudreaux, MD

Associate Professor of Pediatrics
Director of the Comprehensive Thalassemia Program
Clinical Director of Hematology

Aflac Cancer & Blood Disorders Center
Childrens Healthcare of Atlanta
Emory University
Atlanta, Georgia

Stephanie A. Fritch Lilla

Stephanie A. Fritch Lilla, MD

Pediatric Hematologist Oncologist
Director, 
Thalassemia Program
Department of Pediatric Hematology/Oncology
Childrens Minnesota
Minneapolis, Minnesota

Janet L. Kwiatkowski

Janet L. Kwiatkowski, MD, MSCE

Professor of Pediatrics
Perelman School of Medicine of the University of Pennsylvania
Director, Thalassemia Program
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania

Sujit Sheth

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Provided by

ProCE Banner

Supporters

Celgene

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with β-thalassemia.

Learning Objectives

  • Provide optimal care for patients with β-thalassemia, considering the available clinical evidence as well as expert and guideline recommendations

  • Plan therapeutic approaches to reducing transfusion dependence through use of erythroid maturation agent

  • Evaluate emerging gene therapy strategies and their potential role in management of patients with β-thalassemia

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately  hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 22, 2021, through April 21, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Enter patient details and submit case.
4. Review the patient case online or printed out.
5. Submit answers to the Clinical Implications questions and evaluation questions online.

You must respond to all Clinical Implications and evaluation questions to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal

 

The goal of this activity is to improve the competence of learners to apply the latest practice-changing data in the individualized clinical management of patients with β-thalassemia.